Compare ACRE & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | ARMP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 199.7M |
| IPO Year | 2011 | 1996 |
| Metric | ACRE | ARMP |
|---|---|---|
| Price | $3.68 | $3.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $5.00 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 648.5K | 87.6K |
| Earning Date | 11-06-2026 | 11-20-2026 |
| Dividend Yield | ★ 17.65% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.53 | N/A |
| P/E Ratio | $2.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.16 | $2.75 |
| 52 Week High | $5.89 | $14.98 |
| Indicator | ACRE | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 45.21 |
| Support Level | N/A | $2.75 |
| Resistance Level | $4.98 | $3.96 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 84.46 | 37.49 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.